Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

P Jenkins; S Elyan; Sylvie Freeman

doi:10.1016/j.ejca.2006.10.013

Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

P Jenkins, S Elyan, Sylvie Freeman

Immunology and Immunotherapy

Research output: Contribution to journal › Article

27 Citations (Scopus)

Abstract

Audits of adjuvant chemotherapy for breast cancer have revealed that obese patients receive a lower relative dose intensity (RDI). However, interpretation of these studies is complicated by the variable use of cytokine growth factors, empiric dose capping and first cycle dose reductions. We have analysed the impact of obesity on RDI in a cohort of 662 patients that is not confounded by these factors. Patients were classified as overweight or obese on the basis of a body mass index (BMI)>or=25 kg/m2. The mean RDI in patients with BMI>or=25 kg/m2 was actually significantly greater than in those with BMI

Original language	English
Pages (from-to)	544-8
Number of pages	5
Journal	European Journal of Cancer
Volume	43
Issue number	3
DOIs	https://doi.org/10.1016/j.ejca.2006.10.013
Publication status	Published - 1 Feb 2007

Keywords

breast cancer
myelosuppression
obesity
chemotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2006.10.013

Cite this

@article{7b0e14ed09bf494eb0b5dcae75d6b3e1,

title = "Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer",

abstract = "Audits of adjuvant chemotherapy for breast cancer have revealed that obese patients receive a lower relative dose intensity (RDI). However, interpretation of these studies is complicated by the variable use of cytokine growth factors, empiric dose capping and first cycle dose reductions. We have analysed the impact of obesity on RDI in a cohort of 662 patients that is not confounded by these factors. Patients were classified as overweight or obese on the basis of a body mass index (BMI)>or=25 kg/m2. The mean RDI in patients with BMI>or=25 kg/m2 was actually significantly greater than in those with BMI",

keywords = "breast cancer, myelosuppression, obesity, chemotherapy",

author = "P Jenkins and S Elyan and Sylvie Freeman",

year = "2007",

month = feb,

day = "1",

doi = "10.1016/j.ejca.2006.10.013",

language = "English",

volume = "43",

pages = "544--8",

journal = "European Journal of Cancer",

issn = "1879-0852",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

AU - Jenkins, P

AU - Elyan, S

AU - Freeman, Sylvie

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Audits of adjuvant chemotherapy for breast cancer have revealed that obese patients receive a lower relative dose intensity (RDI). However, interpretation of these studies is complicated by the variable use of cytokine growth factors, empiric dose capping and first cycle dose reductions. We have analysed the impact of obesity on RDI in a cohort of 662 patients that is not confounded by these factors. Patients were classified as overweight or obese on the basis of a body mass index (BMI)>or=25 kg/m2. The mean RDI in patients with BMI>or=25 kg/m2 was actually significantly greater than in those with BMI

AB - Audits of adjuvant chemotherapy for breast cancer have revealed that obese patients receive a lower relative dose intensity (RDI). However, interpretation of these studies is complicated by the variable use of cytokine growth factors, empiric dose capping and first cycle dose reductions. We have analysed the impact of obesity on RDI in a cohort of 662 patients that is not confounded by these factors. Patients were classified as overweight or obese on the basis of a body mass index (BMI)>or=25 kg/m2. The mean RDI in patients with BMI>or=25 kg/m2 was actually significantly greater than in those with BMI

KW - breast cancer

KW - myelosuppression

KW - obesity

KW - chemotherapy

U2 - 10.1016/j.ejca.2006.10.013

DO - 10.1016/j.ejca.2006.10.013

M3 - Article

C2 - 17169553

SN - 1879-0852

SN - 1879-2995

VL - 43

SP - 544

EP - 548

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 3

ER -

Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this